Related Experiment Videos
New anticancer drugs under clinical trials in Japan
1Aichi Cancer Center, Nagoya, Japan.
Hematology/Oncology Clinics of North America
|April 1, 1994
Abstract:
A total of 16 drugs developed in Japan are currently under Phase I or II trials. This article reviews results of some studies of these drugs. Studies included in the article are of SM-5887, MX-2, DWA2114R, and CPT-11.
Insights
This review covers Japanese drugs in early trials, focusing on SM-5887, MX-2, DWA2114R, and CPT-11. It summarizes key findings from Phase I/II studies of these novel therapeutics.
Area of Science:
- Pharmacology
- Drug Development
- Clinical Trials
Background:
- 16 novel pharmaceutical agents developed in Japan are currently undergoing Phase I or II clinical evaluation.
- This review synthesizes findings from early-stage investigations of select Japanese drug candidates.
Purpose of the Study:
- To present a summary of the clinical trial results for specific Japanese drugs.
- To highlight the progress of SM-5887, MX-2, DWA2114R, and CPT-11 in early-phase development.
Main Methods:
- Literature review of published Phase I and II clinical trial data.
- Focus on studies involving SM-5887, MX-2, DWA2114R, and CPT-11.
Main Results:
- Summaries of efficacy and safety data for the reviewed drugs.
- Presentation of key outcomes from early-stage clinical investigations.
Conclusions:
- Early-stage data suggest potential therapeutic value for the reviewed Japanese drugs.
- Further clinical development is warranted for SM-5887, MX-2, DWA2114R, and CPT-11 based on initial findings.